A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer
Research
[키워드] 95% CI
Activation
Administered
anticipated
Avelumab
Central nervous system
Complete
conducted
COVID-19
COVID-19 pandemic
criteria
CXCR2
defined
disease
Efficacy
Endpoint
enrolled
Enrollment
histology
immune
Immune cell
Immunotherapy
liver
median
median age
men
Metastasis
monotherapy
Msh2
Mutation
neuroendocrine
open label
Patient
patients
PD-L1
Peripheral blood
phase 2 trial
Phenotyping
poor prognosis
positive
potential mechanism
primary endpoint
progression
progressive disease
Prostate cancer
Radiographic
Result
Safety
secondary
single center
subset
survival
T-cell Response
tested
therapy
Toxicity
Treatment
while
[DOI] 10.1038/s41391-022-00524-7 [Article Type] Research
[DOI] 10.1038/s41391-022-00524-7 [Article Type] Research